

Publication list

1. Nakajima T, Moriguchi M, Mitsumoto Y, Sekoguchi S, Nishikawa T, Takashima H, Watanabe T, Katagishi T, Kimura H, Okanou T, Kagawa K. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. *Mod Pathol*, 17:722-727, 2004. PMID: 15044920
2. Nakajima T, Katagishi T, Moriguchi M, Sekoguchi S, Nishikawa T, Takashima H, Watanabe T, Kimura H, Minami M, Itoh Y, Kagawa K, Okanou T. Tumor size-independence of telomere length indicates an aggressive feature of HCC. *Biochem Biophys Res Commun*, 325:1131-1135, 2004. PMID: 15555545
3. Takashima H, Nakajima T, Moriguchi M, Sekoguchi S, Nishikawa T, Watanabe T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Okanou T. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. *Liver Int*, 25:77-84, 2005. PMID: 15698402
4. Nakajima T, Sekoguchi S, Nishikawa T, Takashima H, Watanabe T, Minami M, Itoh Y, Mizuta N, Nakajima H, Mazaki T, Yanagisawa A, Okanou T. Multifocal intraportal invasion of breast carcinoma diagnosed by laparoscopy-assisted liver biopsy. *World J Gastroenterol*, 11:2360-3, 2005. PMID: 15818755
5. Nakajima T, Moriguchi M, Katagishi T, Sekoguchi S, Nishikawa T, Takashima H, Kimura H, Minami M, Itoh Y, Kagawa K, Tani Y, Okanou T. Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. *Liver Int*, 26:23-31, 2006. PMID: 16420506
6. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Okanou T. A green tea polyphenol, epigallocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. *J Hepatol*, 44:1074-1082, 2006. PMID: 6481065
7. Sekoguchi S, Nakajima T, Moriguchi M, Jo M, Nishikawa T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Tani Y, Okanou T. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. *J Gastroenterol Hepatol*, 22:182-90, 2007. PMID: 17295869
8. Yasuda H, Horie Y, Zen K, Okuda T, Nishikawa T, Sugiyama Y, Mori K, Sakagami J, Yasui K, Tokita K, Kataoka K, Yoshikawa T. Hepatobiliary sarcoidosis: Typical appearance in laparoscopy. *Digestive Endoscopy*, 20:162-165, 2008.
9. Nishikawa T, Nakajima T, Katagishi T, Okada Y, Jo M, Kagawa K, Okanou T, Itoh Y, Yoshikawa T. Oxidative stress may enhance the malignant potential of human

hepatocellular carcinoma by telomerase activation. *Liver Int*, 29:846-856, 2009.

PMID: 19141026

10. Nakajima T, Nakashima T, Okada Y, Jo M, Nishikawa T, Mitsumoto Y, Katagishi T, Kimura H, Itoh Y, Kagawa K, Yoshikawa T. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease – comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. *Pathol Int*, 60:175-183, 2010. PMID: 20403043
11. Jo M, Nishikawa T, Nakajima T, Okada Y, Yamaguchi K, Mitsuyoshi H, Yasui K, Minami M, Iwai M, Kagawa K, Itoh Y, Yoshikawa T. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. *J Gastroenterol*, 46:809-821, 2011. PMID: 21452000
12. Nakajima T, Nakashima T, Yamaoka J, Shibuya A, Konishi E, Okada Y, Jo M, Nishikawa T, Itoh Y, Yoshikawa T. Greater age and hepatocellular aging are independent risk factors for hepatocellular carcinoma arising from non-B non-C non-alcoholic chronic liver disease. *Pathology Int*, 61:572-576, 2011. PMID: 21951665
13. Nishikawa T, Liu L, Yannam RG, Yamamoto T, Basma H, Ito R, Nagaya M, Moscato JD, Stolz DB, Duan F, Kaestner KH, Vodovotz Y, Gutierrez AS, Fox IJ. The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. *Hepatology*, 55:1529-39, 2012. PMID: 22109844
14. Qin Y, Naito Y, Handa O, Hayashi N, Kuki A, Mizushima K, Omatsu T, Tanimura Y, Morita M, Adachi S, Fukui A, Hirata I, Kishimoto E, Nishikawa T, Uchiyama K, Ishikawa T, Takagi T, Yagi N, Kokura S, Yoshikawa T. Heat shock protein 70-dependent protective effect of polaprezinc on acetylsalicylic acid-induced apoptosis of rat intestinal epithelial cells. *Journal of Clinical Biochemistry and Nutrition*, 49:174-81, 2011. PMID: 22128216
15. Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, Kimura H, Nishimura T, Tochiki N, Yasui K, Mitsuyoshi H, Minami M, Kagawa K, Okanoue T, Itoh Y. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. *Liver Int*, 33:301-311, 2013. PMID: 23295058
16. Gen Y, Yasui K, Nishikawa T, Yoshikawa T. SOX2 promotes tumor growth of esophageal squamous cell carcinoma via the AKT/ mTORC1 signaling pathway. *Cancer Sci*, 104:810-816, 2013. PMID: 23510069
17. Nishikawa T, Bellance N, Damm A, Bing H, Zhu Z, Handa K, Yovchev MI, Sehgal V, Moss TJ, Oertel M, Ram PT, Pipinos II, Soto-Gutierrez A, Fox IJ, Nagrath D. A switch in the source of ATP production and a loss in capacity to perform glycolysis are

hallmarks of hepatocyte failure in advance liver disease.

J Hepatol, 60:1203-1211,2014. PMID: 24583248

18. Dutta-Moscato J, Solovyev A, Mi Q, Nishikawa T, Soto-Gutierrez A, Fox IJ, Vodovotz Y. A Multiscale Agent-Based in silico Model of Liver Fibrosis Progression. Front Bioeng Biotechnol, 2:18,2014. doi: 10.3389/fbioe.2014.00018. PMID: 25152891
19. Nishikawa T, Bell A, Brooks JM, Setoyama K, Melis M, Han B, Fukumitsu K, Handa K, Tian J, Kaestner KH, Vodovotz Y, Locker J, Soto-Gutierrez A, Fox IJ. Resetting the transcription factor network reverses terminal chronic hepatic failure. J Clin Invest, 125:1533-1544, 2015. PMID: 25774505
20. Okajima A, Yamaguchi K, Taketani H, Hara T, Ishiba H, Seko Y, Nishimura T, Nishikawa T, Fujii H, Moriguchi M, Mitsuyoshi H, Sumida Y, Yasui K, Minami M, Itoh Y. Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. Hepatol Res, 45:E156-60, 2015. PMID: 25581068
21. Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Tanaka S, Arii S, Itoh Y. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor- β -mediated growth inhibition in hepatocellular carcinoma. Cancer Sci, 106:929-937, 2015. PMID: 25959919
22. Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol, 7:2841-2848, 2015. PMID:26668696
23. Ishiba H, Sumida Y, Kataoka S, Kuroda M, Akabame S, Tomiyasu K, Tanaka M, Arai M, Taketani H, Seko Y, Okajima A, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, **Itoh Y**. Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res, 46:1107-1117, 2016. PMID:26853695
24. Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, Iwai N, Mitsuyoshi H, Sumida Y, Moriguchi M, Yamaguchi K, Nishikawa T, Umemura A, Naito Y, Tanaka S, Arii S, Itoh Y. Genome-wide DNA methylation analysis in hepatocellular carcinoma. Oncol Rep, 35:2228-2236, 2016. PMID: 26883180
25. Okajima A, Sumida Y, Taketani H, Hara T, Seko Y, Ishiba H, Nishimura T, UmemuraA, Nishikawa T, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Liver stiffness measurement to platelet ratio index predicts the

- stage of liver fibrosis in non-alcoholic fatty liver disease. *Hepatol Res*, 2016. doi: 10.1111/hepr.12793. PMID: 27539017
26. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. *Hepatol Res*, 2016. doi: 10.1111/hepr.12840. PMID: 27862719
 27. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. *Hepatol Res*, 2016. doi: 10.1111/hepr.12837. PMID: 27917557
 28. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. *Hepatol Res*, 2016. doi: 10.1111/hepr.12834. PMID: 27925353
 29. Soltys KA, Setoyama K, Tafaleng EN, Soto Gutiérrez A, Fong J, Fukumitsu K, Nishikawa T, Nagaya M, Sada R, Haberman K, Gramignoli R, Dorko K, Tahan V, Dreyzin A, Baskin K, Crowley JJ, Quader MA, Deutsch M, Ashokkumar C, Shneider BL, Squires RH, Ranganathan S, Reyes-Mugica M, Dobrowolski SF, Mazariegos G, Elango R, Stolz DB, Strom SC, Vockley G, Roy-Chowdhury J, Cascalho M, Guha C, Sindhi R, Platt JL, Fox IJ. Host conditioning and rejection monitoring in hepatocyte transplantation in humans. *J Hepatol*, 2016. pii: S0168-8278(16)30750-4. doi: 10.1016/j.jhep.2016.12.017. PMID: 28027971
 30. Kitaichi T, Yasui K, Gen Y, Dohi O, Iwai N, Tomie A, Yamada N, Terasaki K, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Naito Y, Zen Y, Itoh Y. Loss of PAR-3 protein expression is associated with invasion, lymph node metastasis, and poor survival in esophageal squamous cell carcinoma. *Hum Pathol*, 2017. pii: S0046-8177(17)30030-8. doi: 10.1016/j.humpath.2017.01.009. PMID: 28188749
 31. Mitsuyoshi H, Yasui K, Hara T, Taketani H, Ishiba H, Okajima A, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Minami M, Itoh Y. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of nonalcoholic fatty liver

- disease. *Hepatol Res*, 47(13):1459-1468, 2017. doi: 10.1111/hepr.12883. PMID: 28245087
32. Kodo K, Sugimoto S, Nakajima H, Mori J, Itoh I, Fukuhara S, Shigehara K, Nishikawa T, Kosaka K, Hosoi H. Erythropoietin (EPO) ameliorates obesity and glucose homeostasis by promoting thermogenesis and endocrine function of classical brown adipose tissue (BAT) in diet-induced obese mice. *PLoS One*, 12(3): e0173661, 2017. doi: 10.1371/journal.pone.0173661. PMID: 28288167
 33. Gen Y, Yasui K, Kitaichi T, Iwai N, Terasaki K, Dohi O, Hashimoto H, Fukui H, Inada Y, Fukui A, Jo M, Moriguchi M, Nishikawa T, Umemura A, Yamaguchi K, Konishi H, Naito Y, Itoh Y. ASPP2 suppresses invasion and TGF- β 1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer. *Cancer Lett*, 398:52-61, 2017. doi: 10.1016/j.canlet.2017.04.002. PMID: 28400336
 34. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. *Hepatol Res*, 48(3):E42-E51, 2018. doi: 10.1111/hepr.12925. PMID: 28628263
 35. Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. *J Gastroenterol*, 53(3):438-448, 2018. doi: 10.1007/s00535-017-1372-8. PMID: 28744823
 36. Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. *World J Hepatol*, 9(25):1064-1072, 2018. doi: 10.4254/wjh.v9.i25.1064. PMID: 28951778
 37. Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T, Soda T, Yamada N, Dohi O, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Konishi H, Naito Y, Itoh Y. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. *Int J Oncol*, 53(1):237-245, 2018. doi: 10.3892/ijo.2018.4369. PMID: 29658604
 38. Mizuno N, Seko Y, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Itoh Y. Increase in the

- skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. *J Gastroenterol*, 54(2):160-170, 2019. doi: 10.1007/s00535-018-1485-8. PMID: 29948305
39. Furuta M, Moriguchi M, Okuda K, Kataoka S, Mizuno N, Takemura M, Taketani H, Hara T, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Yasui K, Minami M, Itoh Y. Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma. *Dig Dis*, 36(5):385-394, 2018. doi: 10.1159/000489488. PMID: 29969764
 40. Seko Y, Moriguchi M, Hara T, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Yasui K, Minami M, Itoh Y. Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. *Hepatol Res*, 49(4):473-478, 2019. doi: 10.1111/hepr.13296. PMID: 30549372
 41. Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. *Diabetes Metab Syndr Obes*, 11:835-843, 2018. doi: 10.2147/DMSO.S184767. eCollection 2018. PMID: 30568471
 42. Seko Y, Mizuno N, Okishio S, Takahashi A, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Itoh Y. Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. *Hepatol Res*, 49(6):627-636, 2019. doi: 10.1111/hepr.13321. PMID: 30716793
 43. Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H, Fujii H, Shima T, Mitsumoto Y, Ishiba H, Takashima H, Nagao Y, Jo M, Arai M, Hara T, Okajima A, Muramatsu A, Morita A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Itoh Y. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. *Anticancer Res*, 39(9):5149-5156, 2019. doi: 10.21873/anticancer.13710. PMID: 31519627
 44. Taketani H, Nishikawa T, Nakajima H, Kodo K, Sugimoto S, Aoi W, Horike SI, Meguro-Horike M, Ishiba H, Seko Y, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Itoh Y. Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice.

- Diabetes Metab Syndr Obes, 12:1473-1492, 2019. doi: 10.2147/DMSO.S214093. eCollection 2019. PMID: 31692556
45. Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Mizuno N, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci*, 21(1):171, 2019. doi: 10.3390/ijms21010171. PMID: 31881781
 46. Yano K, Seko Y, Takahashi A, Okishio S, Kataoka S, Takemura M, Okuda K, Mizuno N, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. *Diagnostics (Basel)*, 10(2):86, 2020. doi: 10.3390/diagnostics10020086. PMID: 32041289
 47. Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, Kimura H, Fujii H, Ishikawa H, Takaharu Y, Ishiba H, Morita A, Jo M, Nagao Y, Arai M, Hara T, Okajima A, Muramatsu A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Okanoue T, Itoh Y. Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. *Cancers (Basel)*, 12(3):754, 2020. doi: 10.3390/cancers12030754. PMID: 32209994
 48. Seko Y, Moriguchi M, Takahashi A, Okishio S, Kataoka S, Okuda K, Mizuno N, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Itoh Y. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals. *Intern Med*, 59(15):1811-1817, 2020. doi: 10.2169/internalmedicine.4442-20. PMID: 32741890
 49. Terasaki K, Gen Y, Iwai N, Soda T, Kitaichi T, Dohi O, Taketani H, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Konishi H, Naito Y, Itoh Y, Yasui K. SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSK-3 β signaling pathway in esophageal squamous cell carcinoma. *Oncol Lett*, 21(4):269, 2021. doi: 10.3892/ol.2021.12530. PMID: 33717266
 50. Okuda K, Umemura A, Umemura S, Kataoka S, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Kanbara Y, Arbiser JL, Shima T, Okanoue T, Karin M, Itoh Y. Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis. *Cancers*,

13(7):1515, 2021. doi: 10.3390/cancers13071515. PMID: 33806040

51. Okuda K, Umemura A, Kataoka S, Yano K, Takahashi A, Okishio S, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Nakagawa H, Liu Y, Mitsumoto Y, Kanbara Y, Shima T, Okanoue T, Itoh Y. Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. *Front Oncol*, 11:758549, 2021. doi: 10.3389/fonc.2021.758549. eCollection 2021. PMID: 34796113
52. Kataoka S, Umemura A, Okuda K, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Kanbara Y, Arbiser JL, Shima T, Okanoue T, Itoh Y. Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF- β 1/SMAD Signaling and Autophagy in Hepatic Stellate Cells. *Int J Mol Sci*, 22(24):13354, 2021. doi: 10.3390/ijms222413354. PMID: 34948151
53. Soda T, Gen Y, Terasaki K, Iwai N, Kitaichi T, Dohi O, Taketani H, Seko Y, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Konishi H, Naito Y, Itoh Y, Yasui K. Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach. *Sci Rep*, 12(1):5050, 2022. doi: 10.1038/s41598-022-08904-8. PMID: 35322078